[1] Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies[J]. BMJ,2005,330(7491):565-572. [2] Milne F, Redman C, Walker J, et al. The preeclampsia community guideline (PRECOG):how to screen for and detect onset of preeclampsia in the community[J]. BMJ, 2005,330(7491):576-580. [3] 杨孜,王伽略,黄萍,等.重度子痫前期临床发病类型及特点与围产结局的关系[J]. 中华妇产科杂志, 2006,41(5) :302-306. [4] 杨孜,王伽略,黄萍.重度子痫前期终末器官受累不平行性及围产结局探讨[J].中华围产医学杂志,2006,9:10-14. [5] 史俊梅,杨孜,陈蕾. 重度子痫前期患者水肿临床类型分析[J].中华医学杂志,2014,94(17):1342-1345. [6] 杨孜. 生物学标记结合临床风险推动子痫前期预测更上一层楼[J]. 中华围产医学杂志,2011,14(7):385-389. [7] 中华医学会妇产科学分会产科学组. 孕前和孕期保健指南(第1版)[J]. 中华妇产科杂志,2011,46(2):150-153. [8] National Collaborating Centre for Women's and Children's Health (UK).Hypertension in pregnancy:the management of hypertensive disorders during pregnancy[M].London: RCOG Press,2010. [9] 杨孜. 子痫前期预测预防是固步自封,还是探索求进强化预警[J]. 中国实用妇科与产科杂志,2014,30(1):3-7. [10] 史峻梅,杨孜,陈蕾,等. 重度子痫前期患者临床发病前预警信息分析[J]. 中华妇产科杂志, 2009,44(5):337-340. [11] 宋颖, 杨孜, 沈洁, 等. 规律产前检查轻重度子痫前期患者早期临床发病特点分析[J]. 中国实用妇科与产科杂志, 2014, 30(6): 457-461. [12] 杨孜. 早发型子痫前期临床与基础研究并进相得益彰[J]. 中国妇产科临床杂志,2010,11(4):241-243. [13] Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance[J]. BMJ,2010,341:c2207. [14] Magee LA,Helewa M,Moutquin JM,et a1.Diagnosis,evaluation,and management of the hypertensive disorders of pregnancy[J].J Obstet Gynaecol Can,2008,30:S1-48. [15] American Congress of Obstetric and Gynecologists. Hypertetion in pregnancy [J]. Obstet Gynecol, 2013,122,1122-1131. [16] Conde-Agudelo A, Romero R, Kusanovic JP, et al. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and meta-analysis[J]. Am J Obstet Gynecol,2011,204(6):501-503. [17] Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women[J]. Hypertension,2005,45(1):86-91. [18] Sergio F, Maria CD, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone[J]. Hypertens Pregnancy,2006,25(2):115-127. [19] Facchinetti F, Marozio L, Frusca T, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia[J]. Am J Obstet Gynecol,2009,200(1):41-46. [20] de Vries JI, van Pampus MG, Hague WM, et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT[J]. J Thromb Haemost,2012,10(1):64-72. [21] Kupferminc M, Rimon E, Many A, et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia[J]. Blood Coagul Fibrinolysis,2011,22(2):123-126. |